The DOI matches its Crossref record; 300 of the 302 references it cites were found in a registry or an index.
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Open accessAbstract
The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a central focus for engaging the immune system in the fight against cancer. Basic science discoveries elucidating the molecular and cellular biology of the T cell have led to new strategies in this fight, including checkpoint blockade, adoptive cellular therapy and cancer vaccinology. This area of immunological research has been highly active for the past 50 years and is now enjoying unprecedented bench-to-bedside clinical success. Here, we provide a comprehensive historical and biological perspective regarding the advent and clinical implementation of cancer immunotherapeutics, with an emphasis on the fundamental importance of T lymphocyte regulation. We highlight clinical trials that demonstrate therapeutic efficacy and toxicities associated with each class of drug. Finally, we summarize emerging therapies and emphasize the yet to be elucidated questions and future promise within the field of cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Conversely, myeloid-specific overexpression of HIF-1α results in hyperinflammatory, M1-polarized macrophages associated with increased glycolysis, suggesting a link between HIF-1α and M1-polarization [63].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The possible contribution of the adaptive immune system in AD patients to reducing cancer incidence has not been studied (4,5).”
From Alzheimer's Disease–Associated Amyloid-β Precursor Protein Prevents Aging Stress–Induced Mitophagy and Fumarate Depletion to Improve Antitumor Immunity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Typically, PD‐L1 or PD‐L2 are expressed on the surface of cancer cells or antigen‐presenting cells and transduce a signal for cooperation with PD‐1 expression on the cell surface of T lymphocytes to stimulate restraint signaling [272, 273].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [272]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Cited by
Sorted by citations
Items 501–600 of 1,006
Dang, B.-T. N., Duwa, R., Lee, S., Kwon, T. K., Chang, J., Jeong, J., & Yook, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.062 · Cited by 53
Next-generation cancer vaccines and emerging immunotherapy combinations
Brandenburg, A., Heine, A., & Brossart, P. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.003 · Cited by 52
Liposomes-enabled cancer chemoimmunotherapy
Zhang, L., Shi, J., Zhu, M., Huang, Y., Lu, Q., Sun, P., Chen, H., Lai, X. P., & Fang, C. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122801 · Cited by 53
Lee, L. C., & Lo, K. K. (2024) · Small Methods · doi:10.1002/smtd.202400563 · Cited by 52
Optimized circular RNA vaccines for superior cancer immunotherapy
Yu, H., Wen, Y., Yu, W., Lu, L., Yu, Y., Liu, C., Hu, Z., Fang, Z., & Huang, S. (2024) · Theranostics · doi:10.7150/thno.104698 · Cited by 53
Characterizing cell interactions at scale with made-to-order droplet ensembles (MODEs)
Madrigal, J. L., Schoepp, N. G., Xu, L., Powell, C. S., Delley, C. L., Siltanen, C. A., Danao, J., Srinivasan, M., Cole, R. H., & Abate, A. R. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110867119 · Cited by 51
Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development
Liang, J., & Zhao, X. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0004 · Cited by 53
Applications of Single-Cell Omics in Tumor Immunology
Liu, J., Qu, S., Zhang, T., Gao, Y., Shi, H., Song, K., Chen, W., & Yin, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697412 · Cited by 53
Sudarsanam, H., Buhmann, R., & Henschler, R. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.886637 · Cited by 54
The role of α-klotho in human cancer: molecular and clinical aspects
Ligumsky, H., Merenbakh-Lamin, K., Keren‐Khadmy, N., Wolf, I., & Rubinek, T. (2022) · Oncogene · doi:10.1038/s41388-022-02440-5 · Cited by 51
Qian, R., Zhou, Z., Wu, Y., Yang, Z., Guo, W., Li, D., & Lu, Y. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202210935 · Cited by 51
Phulphagar, K. M., Ctortecka, C., Jácome, A. S. V., Klaeger, S., Verzani, E. K., Hernandez, G. M., Udeshi, N. D., Clauser, K. R., Abelin, J. G., & Carr, S. A. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100563 · Cited by 49
Tumor Metabolism-Rewriting Nanomedicines for Cancer Immunotherapy
Dong, X., Xia, S., Du, S., Zhu, M., Lai, X. P., Yao, S. Q., Chen, H., & Fang, C. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00702 · Cited by 53
Wang, C., Sun, X., Feng, L., & Liu, Z. (2024) · BMEMat · doi:10.1002/bmm2.12083 · Cited by 52
The BTLA–HVEM axis restricts CAR T cell efficacy in cancer
Guruprasad, P., Carturan, A., Zhang, Y., Cho, J. H., Kumashie, K. G., Patel, R. P., Kim, K.-H., Lee, J.-S., Lee, Y., Kim, J. H., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01847-4 · Cited by 52
Advances in three-dimensional hydrogel networks for cancer immunotherapy
Mamidi, N., & Salehi, A. O. M. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01133g · Cited by 51
Rai, Z. L., Feakins, R. M., Pallett, L. J., Manas, D., & Davidson, B. R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081609 · Cited by 54
Watkinson, F., Nayar, S. K., Rani, A., Sakellariou, C. A., Elhage, O., Papaevangelou, E., Prokar Dasgupta, A., & Galustian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594620 · Cited by 50
Fatty Acid Metabolism and Cancer Immunotherapy
Luo, Y., Wang, H., Liu, B., & Wei, J. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01223-1 · Cited by 53
Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines
Li, W., Su, J., & Li, Y. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.2c00360 · Cited by 52
CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis
Morgan, H. J., Rees, E., Lanfredini, S., Powell, K. A., Gore, J., Gibbs, A., Lovatt, C., Davies, G. E., Olivero, C., Shorning, B. Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci150750 · Cited by 52
Patel, R. K., Rahman, S., Schwantes, I. R., Bartlett, A. Q., Eil, R. L., Farsad, K., Fowler, K. J., Goodyear, S. M., Hansen, L., Kardosh, A., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.08.012 · Cited by 55
Wang, Z., Ji, X., Zhang, Y., Yang, F., Su, H., Zhang, H., Li, Z., Zhang, W., & Sun, W. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008983 · Cited by 54
Tumor microbiome: roles in tumor initiation, progression, and therapy
Zhang, S., Huang, J., Jiang, Z., Tong, H., Ma, X., & Liu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00248-9 · Cited by 58
The progress and prospects of targeting the adenosine pathway in cancer immunotherapy
Yang, Y., Zhu, L., Xu, Y., Liang, L., Liu, L.-Z., Chen, X., Li, H., & Liu, H. (2025) · Biomarker Research · doi:10.1186/s40364-025-00784-0 · Cited by 55
Organoid co‐culture models of the tumor microenvironment promote precision medicine
Gu, Z., Wu, Q., Shang, B., Zhang, K., & Zhang, W. (2024) · Cancer Innovation · doi:10.1002/cai2.101 · Cited by 47
IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors
Zou, Y., Liu, B., Li, L., Yin, Q., Tang, J., Jing, Z., Huang, X., Zhu, X., & Chi, T. H. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.016 · Cited by 49
Oligometastases: Emerging Evidence
Liu, W., Bahig, H., & Palma, D. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01482 · Cited by 48
Responsive manganese-based nanoplatform amplifying cGAS-STING activation for immunotherapy
He, Q., Zheng, R., Ma, J., Zhao, L., Shi, Y., & Qiu, J. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00374-x · Cited by 49
The immunometabolic ecosystem in cancer
Bantug, G. R., & Hess, C. (2023) · Nature Immunology · doi:10.1038/s41590-023-01675-y · Cited by 53
Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy
Dang, B.-T. N., Kwon, T. K., Lee, S., Jeong, J., & Yook, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.007 · Cited by 51
Jing, W., Wang, G., Cui, Z., Li, X., Zeng, S., Jiang, X., Li, W., Han, B., Xing, N., Zhao, Y., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2312855121 · Cited by 48
Zhou, R., Yu, H., Sheng, T., Wu, Y., Chen, Y., You, J., Yang, Y., Luo, B., Zhao, S., Zheng, Y., et al. (2024) · Advanced Materials · doi:10.1002/adma.202401667 · Cited by 51
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy
Chen, F., Xue, Y., Zhang, W., Zhou, H., Zhou, Z., Chen, T., Yinwang, E., Li, H., Ye, Z., Gao, J., et al. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10211-9 · Cited by 54
The power of phages: revolutionizing cancer treatment
Islam, M. S., Fan, J., & Pan, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1290296 · Cited by 50
A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL
Zanetti, S. R., Velasco-Hernández, T., Gutiérrez‐Agüera, F., Diaz, V. M., Romecín, P. A., Roca-Ho, H., Sánchez‐Martínez, D., Tirado, N., Baroni, M. L., Petazzi, P., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.033 · Cited by 48
Reactive Oxygen Species in Anticancer Immunity: A Double-Edged Sword
Wang, J., Liu, N., Jiang, H., Qian, L., & Xing, D. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.784612 · Cited by 48
Zhang, D. X., Dang, X. T. T., Vu, L. T., Lim, C. M. H., Yeo, E. Y. M., Lam, B. W. S., Leong, S. M., Omar, N. B., Putti, T. C., Yeh, Y. C., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12234 · Cited by 48
Mastrotto, F., Pirazzini, M., Negro, S., Salama, A. D., Martínez‐Pomares, L., & Mantovani, G. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c10757 · Cited by 48
Dóra, D., Bokhari, S. M. Z., Aloss, K., Takacs, P., Desnoix, J. Z., Szklenárik, G., Hurley, P. D., & Lohinai, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032769 · Cited by 48
An Introduction to Fundamentals of Cancer Biology
Sriharikrishnaa, S., Suresh, P. S., & Kabekkodu, S. P. (2023) · Biological and medical physics, biomedical engineering · doi:10.1007/978-3-031-31852-8_11 · Cited by 55
T Cell Antigen Recognition and Discrimination by Electrochemiluminescence Imaging
Yan, Y., Zhou, P., Ding, L., Hu, W., Chen, W., & Su, B. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202314588 · Cited by 48
Liu, J., Zhang, Y., Yang, B., Jia, Y., Liu, R., Ding, L., Shen, Z., & Chen, X. S. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202318530 · Cited by 48
Wang, J., Zhang, Z., Zhuo, Y., Zhang, Z., Chen, R., Li, L., Jiang, X., Nie, D., Liu, C. X., Zou, Z., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.010 · Cited by 48
Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer
Viel, S., Vivier, É., Walzer, T., & Marçais, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01098-w · Cited by 53
Intranasal prime-boost RNA vaccination elicits potent T cell response for lung cancer therapy
Li, H., Hu, Y., Li, J., He, J., Yu, G., Wang, J., & Lin, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02191-1 · Cited by 56
Oncolytic viruses: advanced strategies in cancer therapy
Xiao, D., Zhang, H., Liu, Y., Li, Y., Li, G., & Ning, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02343-3 · Cited by 58
Liberini, V., Laudicella, R., Capozza, M., Huellner, M. W., Burger, I. A., Baldari, S., Terreno, E., & Deandreis, D. (2021) · Molecules · doi:10.3390/molecules26082201 · Cited by 48
PD-L1 siRNA–hyaluronic acid conjugate for dual-targeted cancer immunotherapy
Kim, S., Heo, R., Song, S. H., Song, K., Shin, J. M., Oh, S. J., Lee, H., Chung, J. E., Park, J. H., & Kim, T. W. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.023 · Cited by 48
Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth
Menzel, L., Höpken, U. E., & Rehm, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591741 · Cited by 50
Identification of Potent Reverse Indazole Inhibitors for HPK1
Yu, E. C., Methot, J. L., Fradera, X., Lesburg, C. A., Lacey, B. M., Siliphaivanh, P., Liu, P., Smith, D. M., Xu, Z., Piesvaux, J., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00672 · Cited by 46
What is the status of immunotherapy in thyroid neoplasms?
García‐Álvarez, A., Hernando, J., Carmona-Alonso, A., & Capdevila, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.929091 · Cited by 47
helixCAM: A platform for programmable cellular assembly in bacteria and human cells
Chao, G., Wannier, T. M., Gutierrez, C. S., Borders, N. C., Appleton, E., Chadha, A., Lebar, T., & Church, G. M. (2022) · Cell · doi:10.1016/j.cell.2022.08.012 · Cited by 47
Barsheshet, Y., Voloshin, T., Brant, B., Cohen, G., Koren, L., Blatt, R., Cahal, S., Khalil, T. H., Tov, E. Z., Paz, R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214073 · Cited by 49
Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
Simão, D. C., Zarrabi, K. K., Mendes, J. L., da Luz, R., Garcia, J. A., Kelly, W. K., & Barata, P. C. (2023) · Cancers · doi:10.3390/cancers15051412 · Cited by 47
T cell immunotherapy for cervical cancer: challenges and opportunities
Yu, L., Lanqing, G., Huang, Z., Xin, X., Liang, M., Fa-hui, L., Zou, H., & Min, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1105265 · Cited by 51
“And the difference between TCR-Ts and CART-Ts is that TCR-T have weaker sensitivity and affinity to cancer cells, and because the MHC they recognize can present proteins in cells, TCR-T can recognize proteins in cancer cells (20).”
BackgroundPoly-γ-glutamic acid nanoparticles as adjuvant and antigen carrier system for cancer vaccination
Mohammadzadeh, V., Rahiman, N., Cabral, H., Quader, S., Zirak, M. R., Yazdi, M. E. T., Jaafari, M. R., & Alavizadeh, S. H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.049 · Cited by 48
TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers
Nichakawade, T. D., Ge, J., Mog, B. J., Lee, B. S., Pearlman, A. H., Hwang, M. S., DiNapoli, S. R., Wyhs, N., Marcou, N., Glavaris, S. A., et al. (2024) · Nature · doi:10.1038/s41586-024-07233-2 · Cited by 48
Frey, C., & Etminan, M. (2024) · Antibodies · doi:10.3390/antib13030059 · Cited by 48
Shen, Z., Che, X., Zhang, K., Bai, Y., & Deng, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.014 · Cited by 49
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Borgers, J. S. W., Lenkala, D., Kohler, V. L., Jackson, E. K., Linssen, M. D., Hymson, S., McCarthy, B. J., Cosgrove, E., Balogh, K. N., Esaulova, E., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03418-4 · Cited by 50
The epigenetic hallmarks of immune cells in cancer
Yu, J. H., Xiao, C., Fan, T. T., Deng, Z., Wang, D., Cai, W., Li, J., Liao, T., Li, C., & He, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02255-4 · Cited by 52
Immunotherapy in Prostate Cancer: From a “Cold” Tumor to a “Hot” Prospect
Kwon, W., & Joung, J. Y. (2025) · Cancers · doi:10.3390/cancers17071064 · Cited by 47
Dynamics of thymus function and T cell receptor repertoire breadth in health and disease
Granadier, D., Iovino, L., Kinsella, S. M., & Dudakov, J. A. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00840-5 · Cited by 46
Exploring the Potential of Breast Microbiota as Biomarker for Breast Cancer and Therapeutic Response
Dieleman, S., Aarnoutse, R., Ziemons, J., Kooreman, L. F. S., Boleij, A., & Smidt, M. L. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.02.020 · Cited by 48
Cheng, P., Chen, X., Dalton, R., Calescibetta, A. R., So, T., Gilvary, D. L., Ward, G., Smith, V., Eckard, S. C., Fox, J. A., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.005 · Cited by 47
Sun, J., Yan, C., Xu, D., Zhang, Z., Li, K., Li, X., Zhou, M., & Hao, D. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01692-4 · Cited by 46
Wu, C., Cui, M., Cai, L., Chen, C., Zhu, X., Wu, Y., Liu, J., Wang, H., & Zhang, Y. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c01138 · Cited by 46
Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma
Benboubker, V., Boivin, F., Dalle, S., & Caramel, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.873116 · Cited by 51
Moik, F., & Ay, C. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.01.004 · Cited by 46
Natural killer cells suppress cancer metastasis by eliminating circulating cancer cells
Vyas, M., Requesens, M., Nguyen, T. H., Peigney, D., Azin, M., & Demehri, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1098445 · Cited by 51
Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
Farhangnia, P., Ghomi, S. M., Akbarpour, M., & Delbandi, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155778 · Cited by 46
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
Ruzzi, F., Semprini, M. S., Scalambra, L., Palladini, A., Angelicola, S., Cappello, C., Pittino, O. M., Nanni, P., & Lollini, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612963 · Cited by 46
Amplifying cancer treatment: advances in tumor immunotherapy and nanoparticle-based hyperthermia
Zhang, Y., Li, Z., Huang, Y., Zou, B., & Xu, Y. B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1258786 · Cited by 46
Dong, Z., Liu, Y., Wang, C., Hao, Y., Fan, Q., Yang, Z., Li, Q., Feng, L., & Liu, Z. (2023) · Advanced Materials · doi:10.1002/adma.202308254 · Cited by 47
Yin, S., Yu, Y., Wu, N., Zhuo, M., Wang, Y., Niu, Y., Ni, Y., Hu, F., Ding, C., Liu, H., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.03.008 · Cited by 47
Gharib, E., & Robichaud, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179463 · Cited by 55
Sex hormones, the anticancer immune response, and therapeutic opportunities
Conforti, F., Pala, L., Mitri, D. D., Catania, C., Cocorocchio, E., Laszlo, D., Ceresoli, G. L., Locatelli, M., Facella, F., Pas, T. M. D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.013 · Cited by 48
Cationic Nanoparticle-Based Cancer Vaccines
Heuts, J., Jiskoot, W., OSSENDORP, F. A., & van der Maaden, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050596 · Cited by 46
Harber, J., Kamata, T., Pritchard, C. A., & Fennell, D. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003032 · Cited by 47
Berk, Ş., Kaya, S., Akkol, E. K., & Bardakçı, H. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.153938 · Cited by 46
Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment
Pirš, B., Škof, E., Smrkolj, V., & Smrkolj, Š. (2022) · Cancers · doi:10.3390/cancers14030631 · Cited by 47
Musacchio, L., Cicala, C. M., Camarda, F., Ghizzoni, V., Giudice, E., Carbone, M. V., Ricci, C., Perri, M. T., Tronconi, F., Gentile, M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100536 · Cited by 50
Immunotargeting of Cancer Stem Cells
Köseer, A. S., Gaetano, S. D., Arndt, C., Bachmann, M. P., & Dubrovska, A. (2023) · Cancers · doi:10.3390/cancers15051608 · Cited by 47
Kim, C. G., Koh, J.-Y., Shin, S.-J., Shin, J.-H., Hong, M., Chung, H. C., Rha, S. Y., Kim, H. S., Lee, C.-K., Lee, J. H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101251 · Cited by 45
Yang, B., Zhang, Z., Chen, X., Wang, X.-Y., Qin, S., Du, L., Yang, C., Zhu, L., Sun, W., Zhu, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153454 · Cited by 49
Connecting Metabolic Rewiring With Phenotype Switching in Melanoma
Falletta, P., Goding, C. R., & Vivas, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.930250 · Cited by 46
Liu, P., Ye, M., Wu, Y., Wu, L., Lan, K., & Wu, Z. (2022) · Cancer Medicine · doi:10.1002/cam4.5085 · Cited by 46
Targeting RNA N6-methyladenosine modification: a precise weapon in overcoming tumor immune escape
Li, W., Hao, Y., Zhang, X., Xu, S., & Pang, D. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01652-3 · Cited by 46
The enhancer landscape predetermines the skeletal regeneration capacity of stromal cells
Hochmann, S., Ou, K., Poupardin, R., Mittermeir, M., Textor, M., Ali, S., Wolf, M., Ellinghaus, A., Jacobi, D., Elmiger Juri, A. J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abm7477 · Cited by 46
Tumor-associated fibrosis impairs the response to immunotherapy
Naik, A., & Leask, A. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.04.002 · Cited by 47
Flourishing tumor organoids: History, emerging technology, and application
Yang, Q., Li, M., Yang, X., Xiao, Z., Tong, X., Tuerdi, A., Li, S., & Lei, L. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10559 · Cited by 46
Kar, A., Jain, D., Kumar, S., Rajput, K., Pal, S., Rana, K., Kar, R., Jha, S. K., Medatwal, N., Yavvari, P. S., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf2746 · Cited by 46
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer
Liu, Y., Liu, Z., Yang, Y., Sun, J., Sun, J., & Liu, Y. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02321-y · Cited by 52
Fan, Y., Zhan, M., Junhao, L., Yang, X., Zhang, B., Shi, X., & Hu, Y. M. (2023) · Advanced Science · doi:10.1002/advs.202302119 · Cited by 45
Unveiling the Immune Microenvironment’s Role in Breast Cancer: A Glimpse into Promising Frontiers
Kotsifaki, A., Alevizopoulos, N., Dimopoulou, V., & Armakolas, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015332 · Cited by 46
Immunotherapy resistance in solid tumors: mechanisms and potential solutions
Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 49
Regulation of MHC I Molecules in Glioblastoma Cells and the Sensitizing of NK Cells
Burster, T., Gärtner, F., Bulach, C., Zhanapiya, A., Gihring, A., & Knippschild, U. (2021) · Pharmaceuticals · doi:10.3390/ph14030236 · Cited by 47
Liu, B., Zhu, X., Kong, L., Wang, M., Spanoudis, C. M., Chaturvedi, P., George, V., Jiao, J., You, L., Egan, J. O., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.001 · Cited by 42
The Multifaceted Role of TGF-β in Gastrointestinal Tumors
Sabbadini, F., Bertolini, M., Matteis, S. D., Mangiameli, D., Contarelli, S., Pietrobono, S., & Melisi, D. (2021) · Cancers · doi:10.3390/cancers13163960 · Cited by 44
Metadata
- Authors
- Waldman, A. D., Fritz, J. M., & Lenardo, M. J.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Lenardo, Michael J.
- Venue
- Nature Reviews Immunology
- Published
- 2020-05-20
- Volume
- 20
- Issue
- 11
- Pages
- 651-668
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7238960
- OpenAlex
- W3028523516
- Cited by
- 4,154
- References
- 302
- Citations by year
- 2026: 382 · 2025: 748 · 2024: 867 · 2023: 824 · 2022: 754 · 2021: 511 · 2020: 59
- FWCI
- 58.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Emory University
- National Institutes of Health
- National Institute of General Medical Sciences (T32GM008169)
- National Institute of Allergy and Infectious Diseases
- NHLBI Division of Intramural Research
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, T cells, T cell regulation, immune checkpoint blockade, adoptive cellular therapy, clinical trials, immunotherapy toxicity, history of cancer immunotherapy
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Clinical Trials as Topic, Humans, Immunotherapy, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
